

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTI-VATE)

NCT06858579

Status	RECRUITING
Phase	Phase 3
Sponsor	Dianthus Therapeutics
Enrollment	480 participants

Key Eligibility Criteria

Inclusion (14)

- Must have given written informed consent before any study-related activities are carried out.
 - Weight range between 40 kilograms (kg) and 120 kg.
 - Confirmed diagnosis of CIDP or possible CIDP. Participants must have either typical CIDP or one of the following variants: motor or multifocal CIDP. Diagnosis must be confirmed by the Independent CIDP Review Panel.
 - CIDP Disease Activity Status (CDAS) score e 3 at screening.
 - Must be neurologically stable.
- ... and 9 more (see full listing online)

Exclusion (11)

- Clinical signs or symptoms suggestive of polyneuropathy of causes other than CIDP.
 - Known evidence of central demyelination or known history of myelopathy.
 - History or presence of significant medical/surgical condition including any acute illness or major surgery considered to be clinically significant or that could have a potential impact on safety/efficacy or study procedures.
 - Any other condition, including mental illness or prior therapy that would make the participant unsuitable for this study.
 - Known complement deficiency or history of positive titer for anti-C1 antibodies.
- ... and 6 more (see full listing online)

Locations (158 total)

Clinical Study Site, Birmingham, Alabama, United States
Clinical Study Site, Phoenix, Arizona, United States
Clinical Study Site, Scottsdale, Arizona, United States
... and 155 more locations